Adicet Bio appoints Katie Peng to Board; commercial launch experience from Denali, Genentech

Adicet Bio, Inc.

Katie Peng appointed to Board effective July 10, 2023; board size expanded from 8 to 9 directors.
Ms. Peng received option to purchase 70,200 shares at $3.38/share, vesting over 36 months.
She serves as Chief Commercial Officer at Denali Therapeutics, previously SVP at Genentech.
Led launches of OCREVUS (MS), Evrysdi (SMA), and HEMLIBRA (hemophilia A).
Appointment adds commercial expertise as Adicet advances ADI-001 towards pivotal study.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Katie Peng

Director

ACET · Adicet Bio, Inc.

Effective: 2023-07-10
Filed: July 11, 2023, 7:59 PM ET

the Board appointed Katie Peng to the Board, effective as of July 10, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Katie Peng was appointed as Director at Adicet Bio, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Katie Peng to the Board, effective as of July 10, 2023

View on SEC.gov

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-032449

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.